Harrow Inc

The stock is in a Stage 4 decline with active lower highs/lower lows and a Bearish Pivot Point indicating failed upside control. Price remains below declining short-term EMAs and the 50 SMA, but proximity to immediate support and neutral RSI suggest a potential pause or bounce, making deferred selling preferred until resistance is retested.

• ↑IHEEZO trial shows 58% lower injection discomfort vs peers
• ↑Revenue to grow at 28.2% CAGR, aiming profitability by 2027
• ↓Negative earnings yield and –37.3 P/E highlight valuation strain